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Abstract
Background: Zfra is a 31-amino-acid zinc finger-like protein, which is known to regulate cell death
by tumor necrosis factor (TNF) and overexpressed TNF receptor- or Fas-associated death domain
proteins (TRADD and FADD). In addition, Zfra undergoes self-association and interacts with c-Jun
N-terminal kinase 1 (JNK1) in response to stress stimuli. To further delineate the functional
properties of Zfra, here we investigated Zfra regulation of the activation of p53, WOX1 (WWOX
or FOR), NF-κB, and JNK1 under apoptotic stress.
Results: Transiently overexpressed Zfra caused growth suppression and apoptotic death of many
but not all types of cells. Zfra either enhanced or blocked cell death caused by TRADD, FADD, or
receptor-interacting protein (RIP) in a dose-related manner. This modulation is related with Zfra
binding with TRADD, NF-κB, JNK1 and WOX1, as determined by GST pull-down analysis, co-
immunoprecipitation, and mapping by yeast two-hybrid analysis. Functionally, transiently
overexpressed Zfra sequestered NF-κB (p65), WOX1, p53 and phospho-ERK (extracellular signal-
activated kinase) in the cytoplasm, and TNF or UV light could not effectively induce nuclear
translocation of these proteins. Zfra counteracted the apoptotic functions of Tyr33-
phosphorylated WOX1 and Ser46-phosphorylated p53. Alteration of Ser8 to Gly abolished the
apoptotic function of Zfra and its regulation of WOX1 and p53.
Conclusion: In response to TNF, Zfra is upregulated and modulates TNF-mediated cell death via
interacting with TRADD, FADD and RIP (death-inducing signaling complex) at the receptor level,
and downstream effectors NF-κB, p53, WOX1, and JNK1.
Background
Human WWOX/FRA16D gene encodes a candidate tumor
suppressor WW domain-containing oxidoreductase, des-
ignated WWOX, FOR, or WOX1 [1-3]. This gene is located
Published: 13 June 2007
BMC Molecular Biology 2007, 8:50 doi:10.1186/1471-2199-8-50
Received: 7 December 2006
Accepted: 13 June 2007
This article is available from: http://www.biomedcentral.com/1471-2199/8/50
© 2007 Hong et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Molecular Biology 2007, 8:50 http://www.biomedcentral.com/1471-2199/8/50
Page 2 of 17
(page number not for citation purposes)
on a common fragile site ch16q23.3–24.1 [1,2]. Loss of
heterozygosity (LOH) of WWOX gene has been found in
several types of cancers [[4,5]; reviews]. WWOX/FOR/
WOX1 possesses two N-terminal WW domains (contain-
ing conserved tryptophan residues), a nuclear localization
sequence (NLS) between the WW domains, and a C-termi-
nal short chain alcohol dehydrogenase/reductase (SDR)
domain. WWOX mRNA may undergo alternative splicing,
thereby generating at least 8 mRNAs mainly coding for
proteins with altered SDR domain sequences [4]. Several
protein isoforms have been identified [4]. Nonetheless,
presence of specific protein isoforms in normal and can-
cerous tissues remains to be established.
WWOX/FOR/WOX1 is considered as a candidate tumor
suppressor and proapoptotic protein, whereas its in vivo
function is largely unknown [4]. Under stress conditions,
WOX1 undergoes phosphorylation at Tyr33 and may
translocate to the mitochondria and nuclei to induce
apoptosis in cultured cells and in rat eyes [3,6-9]. Tyr33-
phosphorylated or activated WOX1 binds to the proline-
rich region and phospho-Ser46 of p53, and both proteins
induce apoptosis synergistically [3,6,8]. When WOX1 is
functionally suppressed by antisense mRNA, small inter-
fering RNA (siRNA), or dominant negatives, the stability
of p53 and its apoptotic function are significantly sup-
pressed [3,6,8]. The proapoptotic function of WOX1 is
probably associated, in part, with its interaction with p53,
p73, JNK1 and other transcription factors [4].
To isolate WOX1-binding proteins using yeast two-hybrid
cDNA library screening [3,6,8], we found that WOX1
interacts with a small size 31-amino-acid protein, Zfra
(zinc finger-like peptide that regulates apoptosis) [10].
Zfra belongs to the family of C2H2 type zinc finger pro-
teins [11-13], and has a sequence homology to transcrip-
tion factor forkhead protein xFKHR1 [14]. Zinc finger
proteins interact with DNA and RNA, which is essential
for regulating gene transcription during cell growth and
embryogenesis. Damage to the zinc fingers in DNA repair
proteins may induce carcinogenesis [15]. Zfra mRNA is
expressed in many organs and tissues and most abundant
in the spleen [10]. However, it is absent in several prostate
and breast cancer cell lines [10].
Zfra participates in the signal pathway of tumor necrosis
factor (TNF or TNF-α) [[16,17]; reviews]. Zfra appears to
play a dual role in regulating the cytotoxic effects of TNF
and Fas ligand (FasL) [10]. Zfra either enhances or blocks
the apoptotic functions of transiently overexpressed
receptor adaptor proteins TRADD (tumor necrosis factor
receptor type 1-associated death domain protein) and
FADD (Fas-associated death domain-containing protein)
[10]. TRADD and FADD are recruited to the TNF receptors
when cells are stimulated with TNF or Fas ligand (FasL).
In response to TNF and UV light, Zfra undergoes self-
binding and interacts with JNK1 [10]. JNK1 is a down-
stream effector of the TNF signaling [18-20]. The func-
tional mechanism for the action of Zfra remains to be
established.
In this study, we further investigated the underlying mech-
anisms for the regulatory effect of Zfra on cell death
caused by transiently overexpressed death domain pro-
teins, including TRADD, FADD and RIP (receptor-inter-
acting protein). We determined the role of a conserved
phosphorylation site at serine 8 in conferring Zfra-
induced apoptosis. Also, we examined whether Zfra regu-
lates the activation of transcription factor NF-κB and
tumor suppressors p53 and WOX1 in response to TNF
and UV light, and discussed the biological implications of
their interactions both in vitro and in vivo.
Results
Transiently overexpressed Zfra induces apoptosis
We have previously shown that when ectopic Zfra is stably
expressed in L929 fibroblasts, these cells resist the cyto-
toxic effects of TNF and FasL [10]. In contrast, depending
upon the concentrations used or the extent of expression,
transiently expressed Zfra could either enhance or inhibit
the cytotoxic function of overexpressed death domain
proteins TRADD and FADD [10]. The underlying mecha-
nism of this regard is unknown.
To further examine the role of Zfra-mediated death, a
panel of adherent cell lines was transfected with an EGFP-
tagged Zfra cDNA expression construct by CaPO4. For
non-adherent Molt4 T cells, the DNA construct was intro-
duced by electroporation (Figure 1A). In controls, cells
were transfected with buffer or EGFP vector only. Follow-
ing 48 hr in culture, Zfra induced death of human cell
lines including ovarian ME180, embryonic kidney HEK-
293, neuroblastoma SK-N-SH, Molt4 T lymphocytes, and
breast MCF7 and MDA-MB-231 cells, and murine L929
fibroblasts (Figure 1A). However, Zfra had no effect on
human prostate DU145 and mink lung epithelial Mv1Lu
cells (Figure 1A). Based on our previous observations
[10], an optimal dose of Zfra, 150 ng/well in 96-well
plates, was used to produce ~30–40% death of L929 cells.
Cells with positive protein expression were approximately
60–75%, as determined by fluorescence microscopy (Fig-
ure 1A). EGFP-Zfra was present ubiquitously in cell com-
partments in majority of the tested cells. Interestingly,
EGFP-Zfra was mainly present in the cytoplasm in breast
MDA-MB-231 cells (Figure 1A).
Cells, including HEK-293, SK-N-SH, Molt4 and L929,
express Zfra mRNA, and they are sensitive to Zfra-induced
death [10]. Breast MCF7 and MDA-MB-231 cells do not
express Zfra [10], but were sensitive to Zfra-mediatedBMC Molecular Biology 2007, 8:50 http://www.biomedcentral.com/1471-2199/8/50
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death (Figure 1A). Prostate DU145 is a Zfra-negative cell
line [10], and resisted death by Zfra (Figure 1A). Together,
our data show that resistance to Zfra-mediated death is
not related with the presence or absence of endogenous
Zfra in cells.
We examined the effect of Zfra on anchorage-independent
cell growth [21]. As expected, Zfra blocked colony forma-
tion of L929 cells on agarose plates, as compared to empty
vector controls (Figure 1B).
Zfra induces apoptotic cell death Figure 1
Zfra induces apoptotic cell death. (A) Transiently overexpressed Zfra induced death of human ovarian ME180, embryonic 
kidney HEK-293, neuroblastoma SK-N-SH, breast MDA-MB-231 and MCF7 cells, Molt4 T lymphocytes and murine L929 
fibroblasts, but not human prostate DU145 and mink lung epithelial Mv1Lu cells. These cells were transfected with an EGFP 
(vector) or EGFP-Zfra expression vector (150 ng/well in 96-well microtiter plates) or medium (control) by CaPO4, followed 
by culturing for 48 hr and then staining with crystal violet for determining the extent of death (n = 8; mean ± standard devia-
tion; p < 0.001, EGFP vector-transfected cells versus EGFP-Zfra-transfected cells except DU145 and Mv1Lu; Student's t tests). 
Molt4 T cells were transfected with the DNA constructs by electroporation. Data shown in the buffer and vector (EGFP) con-
trols are from testing L929 cells. Similar data were obtained using other cells. The numbers of cells with positive EGFP or 
EGFP-Zfra protein expression were ~60–75%, as determined by fluorescence microscopy. EGFP-Zfra was present ubiquitously 
in cell compartments in majority of the tested cells (see representative L929 cells; 200× magnification). Interestingly, EGFP-Zfra 
was mainly present in the cytoplasm of MDA-MB-231 cells (400× magnification). (B) In adherence- or anchorage-independent 
growth assay on agarose, Zfra was shown to block colony formation of L929 cells, as opposed to empty vector controls (n = 3, 
p < 0.001; Student's t test). Live colonies were stained with a soluble tetrazolium-based MTS proliferation reagent. (C) Molt4 T 
cells were electroporated with the EGFP-Zfra expression vector, followed by culturing for 48 hr and analyzing the extent of 
apoptosis using Annexin V assay.
C.BMC Molecular Biology 2007, 8:50 http://www.biomedcentral.com/1471-2199/8/50
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To further determine Zfra-mediated apoptosis, Molt4 T
cells were transfected with EGFP-Zfra and cultured for 48
hr. The extent of exposure of phosphatidylserine to cell
surface was determined by Annexin V assay. Zfra increased
the exposure of phosphatidylserine on cell surface (Figure
1C), indicating that cells have undergone apoptosis.
Involvement of conserved serine 8 (Ser8) in Zfra-induced 
apoptosis
Ser8 is a conserved phosphorylation site in Zfra [10]. We
determined the potential role of this site in conferring the
apoptotic function of Zfra. By site-directed mutagenesis,
Ser8 was altered to Gly (S8G). L929 cells were electropo-
rated with EGFP-Zfra, S8G, or EGFP, and the cells were
cultured for 48 hr. Again, transiently overexpressed Zfra
induced death of L929 cells (34.8 ± 8.6%; n = 8), whereas
S8G mutant had a significantly reduced activity in causing
cell death (17.1 ± 5.6%; n = 8) (Figure 2). These observa-
tions suggest that Ser8 phosphorylation is essential for
Zfra-induced apoptosis.
Zfra regulates death domain protein-mediated cell death
TRADD, FADD and RIP are recruited to the TNF receptor
during TNF signaling. RIP interacts with TRADD or FADD
[17]. We have shown that Zfra modulates the apoptotic
function of overexpressed TRADD and FADD [10]. Here,
we continued to examine whether Zfra affects RIP-medi-
ated cell death. We used ME180, HEK-293 and DU145
cells, and DU145 was resistant to Zfra-mediated death
(Figure 1). These cells were cotransfected with "cytotoxic"
doses of cDNA expression constructs of TRADD and/or
Zfra (tagged with EGFP) by CaPO4. Similar experiments
were performed with Zfra with FADD and RIP. Both Zfra
and TRADD induced death of ME180 and HEK-293 cells
in an additive manner (Figure 3). Nonetheless, Zfra did
not increase cell death with FADD or RIP in an additive
manner (Figure 3). In the Zfra-resistant DU145 cells, Zfra
alone did not cause cell death, but increased the cytotoxic
function of TRADD, FADD and RIP by approximately
100–150% (Figure 3).
Next, we tested the effect on death using non-cytotoxic
doses of cDNA constructs. Under this condition, there was
a synergistic enhancement of ME180 cell death by Zfra
and TRADD, FADD or RIP (Figure 4).
Indeed, Zfra regulates cell growth in a biphasic manner. At
low doses, Zfra enhanced growth of Zfra-sensitive L929
cells. But, cell death occurred when higher doses of Zfra
were used, as measured 48 hr post transfection (Figure
5A). Cytotoxic levels of RIP blocked the growth enhance-
ment of Zfra. Similarly, at low levels RIP had no effect on
L929 cell growth, and when in combination, non-toxic
doses of Zfra and RIP increased the cell death (Figure 5B).
Taken together from the above experiments, our data
clearly show that depending upon concentrations or the
extent of expression, Zfra may regulate the function of
death domain proteins TRADD, FADD or RIP in a syner-
gistic or an antagonistic manner.
Zfra physically interacts with TRADD, and binds to the N-
terminal first WW domain and C-terminal SDR domain of 
WOX1
We have utilized a novel cytoplasm-based two-hybrid
analysis in mapping protein/protein interactions between
domains and/or motifs [3,6,8]. Briefly, bait is expressed in
the cytoplasm of yeast cells. When the bait physically
interacts with a cell membrane-anchored target, mutant
yeast cells grow in a selective medium at 37°C as a result
of activation of Ras signal pathway [3,6,8]. We showed
that Zfra interacted with WOX1 from yeast two-hybrid
library screening. To map the Zfra-binding domain(s) in
WOX1, we determined that Zfra physically interacted with
the N-terminal first WW domain of WOX1 (Figure 6).
Alteration of the known phosphorylation site Tyr33 to Arg
in this domain abrogated the binding (Figure 6), suggest-
ing that Tyr33 phosphorylation is needed for WOX1 to
interact with Zfra. During activation, WOX1 undergoes
Tyr33 phosphorylation and nuclear translocation both in
vitro and in vivo [3,6,8,9]. Zfra also bound the C-terminal
SDR domain. This domain has a mitochondria-targeting
region, and Zfra did not bind to this region (Figure 6). In
a negative control, empty vector versus empty vector was
tested. In a positive control, self-binding of MafB is shown
[3,6,8] (Figure 6).
We also determined that Zfra physically interacted with
the full-length TRADD but not RIP, and WOX1 interacted
with TRADD (Figure 6). Together, these observations sug-
gest that Zfra and WOX1 may complex with TRADD, and
this complex affects TNF-mediated cell death.
TNF induces the binding of Zfra with Tyr33-
phosphorylated WOX1, JNK1, and NF-κB
To verify the above observations, we utilized GST (Glu-
tathione S-Transferase) pull-down analysis and co-immu-
noprecipitation to characterize the binding of Zfra with its
partners. Zfra was tagged with GST at its N-terminus.
Recombinant GST-Zfra protein was produced in bacteria,
and then purified using glutathione-Sepharose 4B resin.
Similarly, recombinant GST alone was produced and puri-
fied. Exposure of Zfra-sensitive SK-N-SH cells to TNF
resulted in an increased expression of Zfra and degrada-
tion of IκBα (Figure 7A), indicating that this cell line has
a functional TNF signal pathway. This cell line expresses a
low level of Zfra.
Zfra is able to undergo self-association and binds JNK1
[10]. In GST pull-down assays, GST-Zfra was shown toBMC Molecular Biology 2007, 8:50 http://www.biomedcentral.com/1471-2199/8/50
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interact with endogenous Zfra and WOX1, and TNF barely
increased the binding in SK-N-SH cells (Figure 7B). In
addition, TNF increased the binding of GST-Zfra with
JNK1, NF-κB (p65) and p-WOX1 (Tyr33 phosphor-
ylated), and weakly with p53 in a time-related manner
(Figure 7B and 7C). Zfra could not interact with IκBα,
FADD, RIP and Fas (Figure 7B and 7C). Similarly, in
response to UV light (120 mJoule/cm2), there was an
increased binding of GST-Zfra with endogenous Zfra, p-
WOX1 and JNK1 in SK-N-SH cells, as determined by pull-
down analysis (Figure 7D). UV light increased the binding
of endogenous Zfra with phosphorylated JNK1 (at
Thr183/Tyr185) in SK-N-SH cells, as determined by co-
immunoprecipitation (Figure 7E).
Transiently overexpressed Zfra sequesters WOX1, NF-κB, 
p53 and p-ERK in the cytoplasm
The above data show that endogenous Zfra may physi-
cally interacts with endogenous WOX1, NF-κB and JNK1/
2 in non-stimulated cells. We examined whether tran-
siently overexpressed Zfra sequesters these proteins in the
cytoplasm and prevents their nuclear translocation by
stress stimuli. SK-N-SH cells were electroporated with
EGFP-Zfra or EGFP only, followed by culturing for 24 hr.
Ser8 is involved in Zfra-induced apoptosis Figure 2
Ser8 is involved in Zfra-induced apoptosis. Ser8 is a conserved phosphorylation site in Zfra [10]. Ser8 was altered to Gly 
(S8G). L929 cells were electroporated with EGFP-Zfra, S8G, or EGFP, followed by culturing for 48 hr and staining with crystal 
violet. Transiently overexpressed Zfra induced death of L929 cells (34.8 ± 8.6%; n = 8), whereas S8G mutant had a significantly 
reduced activity in causing cell death (17.1 ± 5.6%; n = 8; p < 0.005, Student's t test; see *). The extent of protein expression is 
shown.
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Transiently overexpressed EGFP-Zfra suppressed nuclear
localization of NF-κB (p65), WOX1, p53, p-ERK (extracel-
lular signal-regulated kinase), but had little or no effect on
JNK1/2 (Figure 8A). TNF induced nuclear translocation of
NF-κB in EGFP control cells, but this event was blocked in
the EGFP-Zfra-expressing cells (Figure 8A). Similarly, in
Zfra-negative breast MCF7 cells, transiently overexpressed
EGFP-Zfra suppressed nuclear translocation of NF-κB and
WOX1 (Figure 8B). Interestingly, transiently overex-
pressed EGFP-Zfra did not have a significant effect on the
nuclear localization of WOX1 in Molt4 T cells (Figure 8C).
However, EGFP-Zfra blocked UV light-induced WOX1
nuclear translocation in Molt4 T cells.
Zfra counteracts the apoptotic function of WOX1
Next, we examined whether Zfra counteracts the apoptotic
function of WOX1. L929 cells were transfected with an
apoptosis-inducing amount of EGFP-WOX1, in the pres-
ence or absence of low doses of EGFP-Zfra by CaPO4. In
parallel with the above observations (Figure 4), low doses
of Zfra enhanced the growth of L929 cells during 24 and
48 hr in culture (Figure 9A; data not shown for 48 hr). Zfra
counteracted WOX1-mediated growth suppression and
death of L929 cells, as determined using crystal violet
staining (Figure 9A). Similar results were observed by
counting the number of apoptotic nuclei (stained with
DAPI; data not shown). Protein expression of EGFP-
Effect of Zfra on TRADD, FADD, or RIP-mediated cell death Figure 3
Effect of Zfra on TRADD, FADD, or RIP-mediated cell death. ME180, HEK-293 and DU145 cells were transfected 
with cytotoxic doses of TRADD, FADD, or RIP cDNA (200 ng/well), in the presence or absence of EGFP-Zfra (200 ng/well) by 
CaPO4. These cells were cultured for 48 hr and then stained with crystal violet. In Zfra-sensitive ME180 and HEK-293 cells, 
Zfra and TRADD increased cell death in an additive manner (n = 8; p < 0.001, TRADD alone versus TRADD/Zfra in combina-
tion; Student's t tests), whereas no additive effect was shown for Zfra with FADD or RIP (n = 8; p > 0.05, FADD or RIP alone 
versus Zfra/FADD or Zfra/RIP; Student's t tests). In Zfra-resistant DU145 cells, Zfra alone did not induce death, but enhanced 
the death by ectopic TRADD, FADD and RIP by ~100–150% increases (n = 8; p < 0.001; Student's t tests). EGFP-Zfra was 
expressed in approximately 60–70% of total cells, as visualized by fluorescence microscopy.BMC Molecular Biology 2007, 8:50 http://www.biomedcentral.com/1471-2199/8/50
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WOX1 and EGFP-Zfra were examined by fluorescence
microscopy (Figure 9A). WOX1 is shown in a perinuclear
area, whereas Zfra is expressed in both cytoplasm and
nucleus.
Similarly, L929 cells were electroporated with WOX1 and/
or Zfra. These cells were cultured for 24 hr, and then proc-
essed for DNA fragmentation in agarose gel electrophore-
sis. WOX1-induced apoptosis was blocked by a non-
apoptotic dose of Zfra (Figure 9B).
Again, L929 cells were then electroporated with apopto-
sis-inducing amounts of WOX1 and/or Zfra, followed by
culturing for 24 and 48 hr, and then processing for cell
cycle analysis by FACS. WOX1 or Zfra alone induced
growth suppression and apoptosis, as evidenced by
increases in the SubG1 phase and decreases in the G1
phase of the cell cycle in cell populations post transfection
for 24 hr (Figure 9C; data not shown for 48 hr). However,
when in combination, Zfra and WOX1 failed to synergis-
tically increase cell death (Figure 9C). Similar results were
observed by testing Zfra with JNK1 (Figure 9C). Overall,
Zfra physically interacts with WOX1 and JNK1, and may
counteract the apoptotic function of these proteins under
stress conditions.
Phosphorylation at Tyr33 is essential for WOX1 to 
counteract Zfra-mediated apoptosis
Phosphorylation of WOX1 at Tyr33 is essential for its
apoptotic function [8]. In parallel with the above observa-
tions (Figure 9), overexpressed WOX1 did not synergisti-
cally increase cell death with Zfra in COS7 cells (Figure
10A). Also, alteration of Tyr33 to Arg (Y33R) abolished
the apoptosis-inducing activity of WOX1 (Figure 10A).
This Y33R mutant could not bind Zfra (Figure 6), and did
not affect Zfra-mediated cell death (Figure 10A). This rela-
tionship was further verified in breast MDA-MB-231 cells
(Figure 10B).
We tested the function of SDR domain and a C-terminal
tail (SDR/C) in WOX1 (Figure 10C). L929 cells were trans-
fected with cDNA constructs for expressing SDR or SDR/
Synergistic enhancement of cell death by non-cytotoxic levels of Zfra and TRADD, FADD or RIP Figure 4
Synergistic enhancement of cell death by non-cytotoxic levels of Zfra and TRADD, FADD or RIP. Zfra-sensitive 
ovarian ME-180 cells were transfected with non-cytotoxic doses of TRADD (FADD or RIP) (20, 40, 80 ng/well) and/or EGFP-
Zfra by CaPO4. Zfra and TRADD, FADD, or RIP synergistically induced ME180 cell death in 48 hr (n = 16; mean ± standard 
deviation; p < 0.001; Zfra, TRADD, FADD, or RIP alone versus Zfra/TRADD, Zfra/FADD, or Zfra/RIP; Student's t tests). Cells 
were stained with crystal violet. EGFP-Zfra was expressed in approximately 60–70% of total cells, as visualized by fluorescence 
microscopy.
ME-180BMC Molecular Biology 2007, 8:50 http://www.biomedcentral.com/1471-2199/8/50
Page 8 of 17
(page number not for citation purposes)
C, followed by culturing for 24 hr in the presence or
absence of a synthetic full-length Zfra peptide (10 μM).
Transiently overexpressed SDR/C exerted cell death. Zfra
peptide alone had no effect but enhanced cell death
caused by SDR/C (Figure 10C). SDR alone could not cause
cell death and Zfra and SDR, in combination, did not
increase the cell death (Figure 10C). Together, these
observations indicate a critical role of Tyr33 phosphoryla-
tion in WOX1 in causing cell death and interacting with
Zfra. Also, when Zfra binds to the C-terminal SDR/C
region, both Zfra and WOX1 may enhance cell death in a
synergistic manner.
Protein expression of ECFP-SDR/C and ECFP-SDR is
shown. The extent of protein expression was in more than
70% of transfected cells, as determined by fluorescence
microscopy. Constructs made for the above experiments
are shown (Figure 10D).
Phosphorylation of p53 at Ser46 is essential for 
counteracting Zfra-mediated apoptosis
Similarly, overexpressed p53 and Zfra nullified each
other's effect in inducing death of COS7 cells (Figure 11).
Zfra(S8G) mutant lost its apoptotic function (Figures 2
and 11), and had no effect in counteracting p53-mediated
cell death (Figure 11). Mutant p53(S46G) had a reduced
activity in causing cell death, and interestingly this mutant
also inhibited Zfra's apoptotic function (Fig. 11). The
extent of protein expression was more than 70%, as deter-
mined by fluorescence microscopy.
Discussion and conclusion
In this study we have shown that the small size Zfra regu-
lates TNF-mediated cell death via directly binding with
TRADD, NF-κB, JNK1, p-ERK and WOX1, and indirectly
with FADD, RIP and p53 (Figure 12). Upon binding with
p55 TNF receptor (p55-TNFR), TNF engages in two signal-
Zfra regulates cell growth in a biphasic manner Figure 5
Zfra regulates cell growth in a biphasic manner. (A) L929 cells were transfected with various amounts of EGFP-Zfra 
and/or a non-toxic dose of RIP (100 ng/well) by CaPO4. Zfra alone enhanced cell growth at low doses, but induced death at 
higher doses (n = 8; mean ± standard deviation). RIP blocked the Zfra-mediated cell growth. (B) Similarly, L929 cells were 
transfected with various amounts of RIP and/or a non-toxic dose of Zfra (60 ng/well). At low levels, RIP had little or no effect 
on cell growth. When in combination, both Zfra and RIP effectively increased the cell death (n = 8; mean ± standard deviation). 
Cells were stained with crystal violet. EGFP-Zfra was expressed in approximately 60–70% of total cells, as visualized by fluores-
cence microscopy.
L929BMC Molecular Biology 2007, 8:50 http://www.biomedcentral.com/1471-2199/8/50
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ing pathways for either protecting cells from death or
committing cells to death. For initiating cell death, p55-
TNFR recruits TRADD, FADD and RIP to generate a death-
inducing signaling complex (DISC) (Figure 12A). Caspase
8 is then recruited to the DISC and becomes activated, fol-
lowed by activating downstream caspases to induce apop-
tosis at both the mitochondrial and nuclear levels [16,17].
We determined that Zfra interacts with TRADD but not
FADD or RIP (Figure 12A). Zfra affects the cytotoxic func-
tion of these death domain proteins via direct and indirect
manners (open arrow). Zfra physically interacts with
WOX1, and that WOX1 binds TRADD. Thus, Zfra and
WOX1 are likely to be recruited to the DISC during TNF
signaling (Figure 12A). This assumption has yet to be val-
idated by co-immunoprecipitation and confocal and
immunoelectron microscopy.
Previously we have shown that WOX1 enhances TNF cyto-
toxicity [3]. WOX1 also enhances the cytotoxic function of
TRADD [3]. Here we determined that both WOX1 and
Zfra counteract with each other in regulating apoptosis.
Zfra either enhances or inhibits the function of death
domain proteins. Thus, the driving force for committing
cells to death in response to TNF is likely coming from a
balanced and counter-balanced work among Zfra, WOX1
and DISC.
In the TNF-initiated protective pathway, Zfra is shown to
interact with TRADD, JNK1 and NF-κB (Figure 12B).
Thus, formation of Zfra-containing regulatory complexes
probably occurs in the TNF signaling cascade. In Step 1, at
the membrane level, Zfra binds TRADD in the presence of
TRADD, TRAF2, RIP and WOX1. In Step 2, a trimolecular
complex of Zfra/JNK1/WOX1 may form when JNK1
Zfra physically binds TRADD and the N-terminal first WW domain and C-terminal SDR domain in WOX1 Figure 6
Zfra physically binds TRADD and the N-terminal first WW domain and C-terminal SDR domain in WOX1. 
Binding of Zfra (as target) with WOX1 (as bait) was mapped by Ras rescue-based yeast two-hybrid analysis (see Materials and 
Methods). Positive binding is evidenced by the growth of mutant yeast at 37°C in a selective medium. Zfra bound to the N-ter-
minal first WW domain and the C-terminal SRD domain of WOX1. Alteration of the known phosphorylation site Tyr33 to 
Arg33 (Y33R) in WOX1 abrogated the binding. Zfra did not interact with the mitochondria-targeting region in the SDR 
domain (Mito-SDR). No yeast cell growth at 37°C was shown when empty vector versus empty vector was tested as a nega-
tive control. In a positive control, the self-binding of MafB is shown. In addition, Zfra was shown to bind the full-length TRADD, 
but not RIP. WOX1 also bound TRADD. Neg cont: negative control; Pos cont: positive control.BMC Molecular Biology 2007, 8:50 http://www.biomedcentral.com/1471-2199/8/50
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becomes activated by the upstream activated MEK. Zfra
binds and counteracts the apoptotic function of JNK1.
Also, JNK1 counteracts the apoptotic function of WOX1
[6]. In Step 3, MEK activates ERK, and that Zfra may bind
and sequester ERK to the cytoplasm. In Step 4, phospho-
rylation of IκBα by IKK causes degradation of IκBα and
release of NF-κB for nuclear translocation. Again, Zfra is
able to bind and sequester NF-κB in the cytoplasm. In
Step 5 and 6, p53 is a downstream effector of TNF signal-
ing [8,22-24]. TNF induces NF-κB activation, and then
NF-κB activates p53 [22]. The non-ankyrin C-terminus of
IκBα physically interacts with cytosolic p53 to prevent
degradation  in vivo, and the complex dissociates in
response to TNF and apoptotic stress [25]. p53 is func-
TNF and UV light increase the binding of Zfra with WOX1, JNK1 and NF-κB, but weakly with p53 in SK-N-SH cells Figure 7
TNF and UV light increase the binding of Zfra with WOX1, JNK1 and NF-κB, but weakly with p53 in SK-N-SH 
cells. (A) Exposure of SK-N-SH cells to TNF (50 ng/ml) for 40 min resulted in upregulation of Zfra and degradation of IκBα. 
(B) In GST pull-down analysis using SK-N-SH cells, TNF increased the binding of GST-Zfra with NF-κB (p65) and JNK1 
(greater than 50%), and weakly with p53 but not IκBα. GST-Zfra physically interacted with endogenous Zfra and WOX1, and 
TNF limitedly increased the binding (less than 30%). In negative controls, GST alone could not bind the above-indicated pro-
teins. The relative amounts of GST and GST-Zfra used in the pull down are shown. One-twentieth amounts of protein input 
for endogenous Zfra and other indicated proteins are shown in Western blotting. (C) Similarly, during a 10-min treatment, 
TNF increased the binding of GST-Zfra with p-WOX1, but not with FADD, RIP, IκBα and Fas. (D) SK-N-SH cells were 
exposed to UV light (120 mJoule/cm2) and then cultured for 1 hr, followed by processing GST pull-down analysis. UV light 
increased the binding of endogenous Zfra with p-WOX1 and JNK1. (E) By co-immunoprecipitation, UV light (120 mJoule/cm2) 
increased the binding of endogenous Zfra with itself and p-JNK1 (at Thr183/Tyr185) (greater than 50% increase), but limitedly 
with WOX1 (less than 20% increase), in SK-N-SH cells.BMC Molecular Biology 2007, 8:50 http://www.biomedcentral.com/1471-2199/8/50
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tionally associated with WOX1, and both proteins may
induce apoptosis synergistically [3,4,6,8]. Thus, an in vivo
complex of IκBα/p53/WOX1 is likely (Chang et al., sub-
mitted), and that Zfra may regulate the formation of this
complex. We show that ectopic Zfra blocks UV light-
induced p53 nuclear translocation or activation, suggest-
ing a negative regulation for the cell death event. Ser46-
phosphorylated p53 is known to play a critical role in
apoptosis [8,25-29]. That is, Zfra may prevent cell death
by blocking the apoptotic function of Ser46-phosphor-
ylated p53. The IκBα/p53/WOX1 or p53/WOX1 may
translocate to the mitochondria (Chang et al., submitted).
Whether this event is blocked by Zfra is unknown.
Presence of two cysteine residues in the amino acid
sequence of Zfra suggests the likely presence of a dimeric
Transiently overexpressed Zfra sequesters NF-κB, WOX1, p53 and ERK in the cytoplasm Figure 8
Transiently overexpressed Zfra sequesters NF-κB, WOX1, p53 and ERK in the cytoplasm. Breast MCF7 and neu-
roblastoma SK-N-SH cells were electroporated with an EGFP-Zfra construct or EGFP only, cultured overnight, and exposed 
to TNF for 40 min. Expression of GFP and GFP-Zfra is shown (A, B). (A) Without stimulation, EGFP-Zfra alone inhibited 
nuclear localization of NF-κB (p65), WOX1, p53 and p-ERK (Y204 phosphorylated) in SK-N-SH cells, whereas it had little or 
no effect on JNK1/2. TNF (50 ng/ml) could not induce nuclear translocation of endogenous JNK1/2, NF-κB (p65), p-ERK, p53 
and WOX1 in Zfra-expressing cells during treatment for 40 min. (B) Similarly, in MCF7 cells, EGFP-Zfra suppressed nuclear 
localization of NF-κB and WOX1, and TNF could not induce nuclear translocation of these proteins. (C) EGFP-Zfra did not 
have a significant effect on the nuclear localization of WOX1 in Molt4 T cells; however, it blocked UV light-induced nuclear 
translocation of WOX1. Ectopic expression of EGFP and EGFP-Zfra in the above cells is shown in each panel. The levels of 
cytosolic α-tubulin are regarded as loading controls.
A. B.
C.BMC Molecular Biology 2007, 8:50 http://www.biomedcentral.com/1471-2199/8/50
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form in cells [10]. Also, whether Zfra covalently interacts
with specific proteins remains to be established. As deter-
mined by GST-pull down analysis, both TNF and UV light
are able to increase self-association of Zfra, supporting the
presence of dimers in vivo [10]. Zfra is inducible under
stress conditions [10]. We show that at low levels Zfra
enhances cell growth, and yet overexpressed Zfra induces
cell death. Ectopic Zfra also blocked adherence-independ-
ent growth of L929 fibroblasts, suggesting that it may act
as a tumor suppressor to block cancer growth and progres-
sion. Zfra is most abundant in the spleen, whereas its role
in regulating immune cell differentiation and functions is
unknown. However, it is reasonable to suggest that Zfra-
regulated TNF signaling is likely to play a role in the lym-
phocyte differentiation. We also determined that absent
expression of Zfra is found in several breast and prostate
Zfra antagonizes the apoptotic function of WOX1 and JNK1 Figure 9
Zfra antagonizes the apoptotic function of WOX1 and JNK1. (A) L929 cells were transfected with a cytotoxic dose of 
EGFP-WOX1 in the presence or absence of low doses of EGFP-Zfra by CaPO4 (n = 8). The cells were cultured 24 and 48 hrs 
and stained with crystal violet. Zfra blocked WOX1-mediated growth suppression and death in 24 hr (data not shown for 48 
hr). Expression of EGFP-tagged Zfra and WOX1 is shown, as determined by fluorescence microscopy (400× magnification). 
(B) Similarly, L929 cells were electroporated with WOX1 and/or Zfra, cultured 48 hr, and then processed for DNA fragmen-
tation. An apoptosis-inducing amount of WOX1 and a non-apoptosis-inducing dose of Zfra were used. In a positive control, 
cells were treated with staurosporine (stauro; 500 nM) for 16 hr. In negative controls, cells were electroporated with medium 
or GFP vector only. ep, electroporation. (C) L929 cells were electroporated with an apoptosis-inducing amount of WOX1 
and/or Zfra, or JNK1 (or medium only), and cultured for 24 and 48 hrs, respectively. Apoptosis occurred in 24 hr, as evidenced 
by increased percentages of cells in the subG1 phase from cell cycle analysis (data not shown for 48 hr). WOX1, JNK1, or Zfra 
alone suppressed cell growth, as indicated by reduced cell populations at the G1. However, both Zfra and WOX1 or JNK1 
could not increase apoptosis in a synergistic manner. X-axis: DNA content; Y-axis: Cell numbers.
C.BMC Molecular Biology 2007, 8:50 http://www.biomedcentral.com/1471-2199/8/50
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cancer cell lines [10], implying that Zfra deficiency may
provide a growth advantage for cancer cells. Majority of
zinc finger proteins participate in gene transcription and
embryonic development [30-32]. Synthetic peptides have
been shown promises in therapy to modulate the tran-
scriptional activities of endogenous zinc finger proteins
[33,34]. Shortening and/or modification of the naturally
occurring Zfra may be of therapeutic value in controlling
cancer cell growth and death.
Zfra is distributed ubiquitously in cellular compartments.
In response to TNF, a portion of cytosolic Zfra appears to
translocate to the cell membrane area and binds TRADD.
Death domain/death domain interaction is responsible
Phosphorylation of WOX1 at Tyr33 is essential for its apoptotic function and for counteracting Zfra-mediated cell death Figure 10
Phosphorylation of WOX1 at Tyr33 is essential for its apoptotic function and for counteracting Zfra-mediated 
cell death. (A) Transiently overexpressed EGFP-Zfra and EGFP-WOX1 induced death of COS7 fibroblasts (n = 8, mean ± 
standard deviation). Zfra counteracted with WOX1 in causing cell death. Alteration of Tyr33 to Arg33 (Y33R) abolished the 
apoptosis-inducing activity of WOX1, and this mutant did not block Zfra-mediated cell death. Expression of EGFP-tagged Zfra, 
WOX1 and WOX1(Y33R) is shown in fluorescent micrographs (400× magnification). WOX1 is shown in the perinuclear area, 
whereas the Y33R mutant tends to aggregate in the nuclei. Zfra is expressed ubiquitously in cells. (B) Similar experiments 
were carried out in breast MDA-MB-231 cells. Again, Zfra and WOX1 did not increase cell death in a synergistic manner (n = 
8, mean ± standard deviation). The Y33R mutant lost its apoptotic function and had no apparent effect on Zfra-mediated cell 
death. (C) L929 cells were transfected with the SDR domain plus a C-terminal tail (SDR/C) or the SDR domain alone (tagged 
with ECFP at the N-terminus). These cells were cultured for 24 hr in the presence or absence of a synthetic full-length Zfra 
peptide (10 μM), and the extent of cell death was determined by crystal violet staining. Zfra enhanced cell death caused by 
SDR/C (n = 8, mean ± standard deviation). SDR alone could not cause cell death, and Zfra did not increase the cell death. Pro-
tein expression of ECFP-SDR/C and ECFP-SDR is shown. (D) Constructs made for the above experiments are shown.
A. COS7 cells B. MDA-MB-231 cells
C. L929 cells D. ConstructsBMC Molecular Biology 2007, 8:50 http://www.biomedcentral.com/1471-2199/8/50
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for TRADD binding with p55-TNFR, FADD and RIP.
Whether Zfra binds to the death domain is unknown.
Sequence alignment analysis shows a common structural
motif in TRADD, JNK1, NF-κB, and the N-terminal WW
domain and C-terminal SDR domain of WOX1. Whether
this motif interacts with Zfra remains to be established.
WWOX/WOX1 is known to interact with p53, p73, JNK1,
AP-2γ, and ErbB4 [3,6,35-37], suggesting its role of the
regulation of gene transcription. Both in vivo and in vitro
studies have shown that overexpressed WWOX1/WOX1
suppresses tumor growth in nude mice, and induces
apoptosis in cultured cells [3,6,8,9,38,39]. Overexpressed
WW and SDR/C domains induce cell death [3]. Most
interestingly, the C-terminal tail of WOX1 is needed to
work together with SDR in causing cell death. In stark con-
trast, non-invasive breast and prostate cancers may have
upregulated expression of WWOX/WOX1, Tyr33 phos-
phorylation and WWOXv2/WOX2 (and other family pro-
teins if present) [40-42]. Downregulation of WOX1 and
WOX2 promotes neurodegeneration in Alzheimer's dis-
ease, suggesting its protective role against neurodegenera-
tion [43]. FOR (WWOX/WOX1) is shown to protect
against the effects of ionizing radiation in Drosophila [44].
These observations support a pro-survival role of WOX1
in vivo [4].
In domain/domain mapping by yeast two-hybrid analy-
sis, Zfra was shown to bind the N-terminal Tyr33-phos-
phorylated WW domain of WOX1. Alteration of this
phosphorylation site abolishes the binding interaction.
Also, it interacts with the C-terminal SDR domain of
WOX1. Since Zfra is a small peptide, its simultaneous
binding to these domains in WOX1 under physiologic
and stress conditions is very likely. Our supporting evi-
dence shows that stress stimuli induce phosphorylation of
WOX1 at Tyr33 and Zfra at Ser8, and that the Zfra/WOX1
complex co-translocates to the mitochondria to regulate
cell death via the mitochondrial pathway (Hsu et al., sub-
mitted). Also, in this study we found that Zfra enhances
the apoptotic activity of SDR domain and the C-terminal
tail of WOX1.
Overexpressed Zfra may nullify the apoptotic activities of
WOX1 and p53. An apparent mechanism is that overex-
pressed Zfra sequesters transcriptional factors in the cyto-
plasm. For example, ectopic Zfra restricts nuclear
localization of endogenous WOX1, p53, ERK, and NF-κB
(p65), indicating that an upregulated level of Zfra may
control the transcriptional system in cells under stress
conditions.
Taken together, we have identified a molecular pathway
underlying Zfra regulation of TNF cytotoxic function. Zfra
interacts with TRADD and binds downstream NF-κB, p53,
JNK1 and WOX1 of the TNF signal pathway, thereby
either enhancing or restricting TNF-mediated cell death.
Methods
Cell lines, antibodies and chemicals
Majority of our experiments were performed using murine
L929 fibroblasts, monkey kidney COS7 fibroblasts and
human Molt4 T lymphocytes for ectopic gene expression.
In addition, the following cell lines were cultured and
tested for their sensitivity to Zfra-mediated death: 1)
human neuroblastoma SK-N-SH cells, 2) human ovarian
ME180 cells, 3) human breast MDA-MB-231 and MCF7
cells, 4) human embryonic kidney HEK-293 fibroblasts,
5) human prostate DU145 cells, and 6) mink lung epithe-
lial Mv1Lu cells. Recombinant TNF-α was from PeproTech
and R&D Systems. We have produced specific antibodies
against the NH- and COOH-termini of WOX1, recom-
Phosphorylation of p53 at serine 46 (S46) is essential for  counteracting Zfra-mediated cell death Figure 11
Phosphorylation of p53 at serine 46 (S46) is essential 
for counteracting Zfra-mediated cell death. COS7 
cells were co-transfected with both p53 and/or Zfra by elec-
troporation, followed by culturing for 24 hr and then deter-
mining the extent of cell death by staining with crystal violet. 
In addition, the cells were also introduced with mutants of 
p53 (S46) and/or Zfra(S8G). The results show that p53 and 
Zfra nullified each other's activity in causing cell death (n = 8, 
mean ± standard deviation). The apoptotic function of both 
Zfra(S8G) and p53(S46G) was significantly reduced. S8G 
mutant had no effect in reducing p53-mediated cell death.
COS7 cellsBMC Molecular Biology 2007, 8:50 http://www.biomedcentral.com/1471-2199/8/50
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binant GST-WOX1 and Tyr33-phosphorylated WOX1
[3,6,43,45], synthetic Zfra peptide [10], and recombinant
GST-Zfra [10]. The following specific antibodies were
from Santa Cruz Biotechnology: p-JNK1 (phospho-JNK1
at Thr183/Tyr185), WWOX, NF-κB, IκBα, FADD, and
p53. Anti-WWOX IgG, N-19 and P-20, were kind gifts of
Santa Cruz Biotechnology. α-Tubulin antiserum was from
Accurate Chemical, and anti-RIP from Pharmingen/BD
Biosciences.
Zfra and WOX1 cDNA constructs and transient gene 
expression
Zfra was constructed in CMV-based mammalian expres-
sion vectors pCR3.1 (Invitrogen) and pEGFPC1
(enhanced green fluorescent protein; cloning site EcoR1;
Clontech) [10]. Murine full length WOX1, Y33R mutant,
WW domains, SDR domain, and SDR domain with a C-
terminal tail were constructed in pCR3.1, pEGFPC1 and
pECFGC1 vectors [3,6,43]. Human p53 and p53(ΔS46)
cDNAs were constructed in pDsRed-N1 (Clontech), as
described [8]. Where indicated, cell lines were transfected
A schematic model of Zfra/WOX1 involvement in TNF signaling Figure 12
A schematic model of Zfra/WOX1 involvement in TNF signaling. TNF is able to initiate two counteractive pathways 
– one apoptotic and the other protective. (A) In the death pathway, binding of TNF to the cognate p55-TNF receptor (TNFR) 
results in recruitment of death domain proteins TRADD, FADD and RIP, thus generating the so called death-inducing signaling 
complex (DISC). Caspase 8 and downstream effectors are then activated to induce cell death at the mitochondrial and nuclear 
levels [16,17]. In this study, we discovered that Zfra physically interacts with TRADD and WOX1, and that WOX1 binds 
TRADD. Thus, Zfra and WOX1 are likely to be recruited to the DISC. WOX1 enhances TNF cytotoxicity [3], and Zfra coun-
teracts the WOX1 function. Zfra either enhances or inhibits the function of death domain proteins (open arrow). Thus, the 
ying and yang of cell death depends upon the strength of DISC formation and the counteractive or enhancing force of Zfra. (B) 
In the protective pathway, p55-TNF recruits TRADD, TRAF2 and RIP, followed by activating several downstream adaptors and 
finally JNK1 and NF-κB. We determined that overexpressed Zfra sequesters p53, WOX1, and NF-κB in the cytoplasm. Thus, 
Zfra is likely to bind and block the function of these proteins during TNF signaling (see each step marked by a number). In 
Step 1, at the membrane level, Zfra binds TRADD in the presence of TRADD, TRAF2, RIP and WOX1. In Step 2, a trimo-
lecular complex of Zfra/JNK1/WOX1 may form when JNK1 is activated by the upstream activated MEK. Zfra binds and coun-
teracts the apoptotic function of JNK1. Also, JNK1 counteracts the apoptotic function of WOX1 [6]. In Step 3, MEK activates 
ERK, and that Zfra may bind and sequester ERK to the cytoplasm. In Step 4, phosphorylation of IκBα by IKK causes degrada-
tion of IκBα and release of NF-κB for nuclear translocation. Again, Zfra is able to bind and sequester NF-κB in the cytoplasm. 
In Step 5 and 6, TNF induces NF-κB activation, and then NF-κB activates p53 [22]. The non-ankyrin C-terminus of IκBα phys-
ically interacts with cytosolic p53 [25]. p53 is functionally associated with WOX1, and both proteins may induce apoptosis syn-
ergistically [3,4,6,8]. Thus, an in vivo complex of Zfra with IκBα/p53/WOX1 or p53/WOX1 is likely (Chang et al., submitted).BMC Molecular Biology 2007, 8:50 http://www.biomedcentral.com/1471-2199/8/50
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with Zfra, WOX1 or p53 constructs, or empty vectors (15–
600 ng/well) by calcium phosphate (CaPO4) or electro-
poration [3,6,8,10,43]. In electroporation, cells were
transfected with the indicated expression constructs in the
presence of albumin to enhance gene expression and
reduce electric shock-induced accidental cell death [8].
Post transfection for 24–48 hr, the extent of cell growth or
death was examined by crystal violet staining, cell cycle
analysis by propidium iodide staining and fluorescence
activated cell sorting (FACS), Annexin V assay, and DNA
fragmentation analyses [3,6,8,43].
Site-directed mutagenesis
The conserved phosphorylation site Ser8 in Zfra was
mutated using QuikChange site-directed mutagenesis Kit
(Stratagene). PCR primers for S8G-Zfra mutant were
designed as follows: 1) S8G forward, GCAGAAG-
GTCGTCTGGCTGTAAATATTGTGA; 2) S8G reverse,
TCACAATATTTACAGCCAGACGACCTTCTGC.
Soft agarose colony survival assay
Adherence-independent or transforming cell growth was
performed in a soft agarose colony survival assay [21].
Briefly, L929 cells were electroporated with expression
constructs of EGFP-Zfra or EGFP alone. These cells were
plated at a density of 3 × 104 cells/35-mm dish in triplicate
in RPMI 1640, 10% fetal bovine serum, 0.8% agarose, and
10 mM Hepes. Dishes were incubated in a humidified
CO2 incubator at 37°C for 3 weeks. The resulting colonies
were stained with a soluble tetrazolium-based MTS cell
proliferation reagent (Promega), and live colonies (with
brown color) were counted [21].
Electroporation, immunoprecipitation, and GST-Zfra pull-
down assays
Cells were suspended in serum-free culture medium, con-
taining 500 μg/ml bovine albumin, and electroporated
with an EGFP-Zfra or EGFP construct (20 μg DNA/3 × 106
cells; 180 volt and 50 msec; BTX ECM 830 Square Wave
Electroporator; Genetronics) [3,6,8,43]. Albumin
enhanced both the transfection efficiency and gene
expression by 3–5 folds. These cells were cultured 24–48
hr and then exposed to UV light or TNF-α for indicated
times. Cytosolic and nuclear protein fractions were pre-
pared using an NE-PER nuclear and cytosolic extraction
kit (Pierce), followed by quantification, SDS-PAGE and
Western blotting [3,6,8,43]. Where indicated, we per-
formed 1) immunoprecipitation using specific antibodies
against Zfra, and 2) pull-down assays using glutathione-
Sepharose 4B beads coated with GST (Glutathione S-
Transferase) or GST-Zfra to examine the presence of Zfra-
binding proteins [3,6,8,10,43].
Cytoplasmic yeast two-hybrid analysis
Ras rescue-based yeast two-hybrid analysis (CytoTrap,
Stratagene) was performed as described [3,6,8]. Briefly, a
cytosolic Sos-tagged bait protein is designed for binding
to a cell membrane-anchored target protein (tagged with
a myristoylation signal). This binding activates the Ras
signal pathway in yeast and allows mutant yeast cdc25H to
grow at 37°C using a selective agarose plate containing
galactose. Without binding, yeast cells cannot grow at
37°C. We made the following bait constructs (in pSos vec-
tor): 1) a murine full-length WOX1, 2) the first WW
domain and an NH2-terminal WW domain area of
WOX1, 3) a COOH-terminal SDR domain area of WOX1
and a mitochondria-targeting region in this domain, and
4) a Y33R mutant in the WW domain area [3,6,8]. For tar-
get, a construct for Zfra was made in pMyr vector. Where
indicated, full-length TRADD and RIP cDNAs were sub-
cloned in pMyr (as target) or pSos (as bait). TRADD and
RIP cDNAs were gifts of Dr. D. Goedell of Tularik/Amgen.
Control constructs for the binding experiments were
human MafB (in both pMyr and pSos) [3,6,8].
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